Planning Treatment Strategies for Older Adults with Myeloma: Considerations for Assessment of the Elderly/Frail Patient
Release Date: February 25, 2021
Expiration Date: February 25, 2022
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
It is important to assess age and fitness when formulating management approaches for a patient with multiple myeloma. In this newsletter, Dr. Tuchman explains the optimal method for assessing the impact of aging and the appropriate considerations for evaluating older patients. He also discusses the different geriatric assessments and instruments best suited to assess elderly patients with multiple myeloma.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Describe the influence of patient age and the common comorbidities associated with the elderly/frail population when planning treatment regimens
- Employ current treatment guidelines and recommendations when devising therapeutic strategies for elderly/frail patients with myeloma
- Monitor and manage treatment-emergent toxicities with rapid and effective strategies to ensure optimal therapeutic outcomes and patient safety
Planning Treatment Strategies for Older Adults with Myeloma: Considerations for Assessment of the Elderly/Frail Patient – Sascha Alexander Tuchman, MD, MHS
Instructions for Participation and Credit
This activity is eligible for credit through February 25, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Sascha Alexander Tuchman, MD, MHS
Associate Chief for Outpatient Clinics and Outreach
Division of Hematology and Oncology
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Dr. Sascha Alexander Tuchman received his medical degree from Georgetown University School of Medicine. He was a resident and chief resident at Duke University Medical Center, a fellow at Duke Cancer Institute, and completed a master’s degree in health sciences at Duke University School of Medicine. Dr. Tuchman is Associate Professor of Medicine and Associate Chief for Outpatient Clinics and Outreach, Division of Hematology and Oncology at the University of North Carolina at Chapel Hill.
Dr. Tuchman manages patients with multiple myeloma (MM), amyloidosis, and other plasma cell disorders and has conducted NIH-supported lab research. His current efforts focus on clinical research in treating MM patients at high risk for toxicity due to advanced age or other comorbidities; developing novel drugs in treating patients with MM; and optimizing management for amyloidosis.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-006-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sascha Tuchman has received honoraria as a consultant from Oncopeptides, AB and Sanofi.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.